Evidence map›Paper›PMID 29246293›Full record

ArticleMolecular therapy. Nucleic acids2017

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK.

Hua Jin, Qing Li, Fenghao Cao, Shu-Nan Wang, Ren-Tao Wang, Yun Wang, Qun-You Tan, Cheng-Run Li, Hua Zou, Dong Wang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Identification ofFrontiers in oncology · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Hua JinDepartment of Thoracic Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China; Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
Qing LiCancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Fenghao CaoHelong City Hospital of Traditional Chinese Medicine, Helong 133500, China.
Shu-Nan WangDepartment of Radiology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Ren-Tao WangDepartment of Respiratory, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Yun WangDepartment of Pathology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Qun-You TanDepartment of Thoracic Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Cheng-Run LiDepartment of Thoracic Surgery, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Hua ZouCancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Dong WangCancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Cheng-Xiong XuCancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. Electronic address: xuchengxiong@hanmail.net.
Daping Hospital · CNArmy Medical University · CNChinese People's Liberation Army · CNAnyang Hospital of Traditional Chinese Medicine · CNPeople's Liberation Army No. 150 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulated miRNAs play important role in K-ras mutation or smoking caused lung tumorigenesis. Here, we investigate the role and mechanism of miR-124 in K-ras mutation or smoking-caused lung tumorigenesis and evaluate the therapeutic potential of miR-124 agomiR in K-ras mutation or smoking-caused lung cancer treatment. Our data show that smoking suppresses miR-124 expression, and decreased miR-124 expression is inversely correlated with the p-Akt level and predicts poor overall survival in non-small-cell lung cancer (NSCLC) patients. The overexpression of miR-124 suppressed NSCLC growth by inhibiting the Akt pathway by targeting Akt1 and Akt2. In addition, the systemic delivery of miR-124 agomiR dramatically suppressed tumorigenesis in both NNK-induced lung cancer model and K-ras

Indexed as

Akt activationK-ras mutation-induced lung tumorigenesislung cancermiR-124NNK-induced lung cancer

Identifiers

PMID29246293
PMCPMC5633347
OpenAlexW2755937982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.